Related Experiment Video
Updated: Mar 29, 2026
Induction and Analysis of Oxidative Stress in Sleeping Beauty Transposon-Transfected Human Retinal Pigment Epithelial Cells
Published on: December 11, 2020
Gene Expression Profiling of H9c2 Cells Subjected to H2O2-Induced Apoptosis with/without AF-HF001
Guping Wang1, Chunlei Tang, Guijun Yan
1School of Pharmaceutical Science, Jiangnan University.
Insights
A new drug candidate, AF-HF001, effectively reduces oxidative stress and heart cell death in laboratory studies. This compound shows promise for treating heart failure by protecting cardiomyocytes from damage.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Molecular Biology
Background:
- Heart failure is a significant global health concern requiring novel therapeutic strategies.
- Previous research identified AF-001 as a compound that can mitigate cardiac defects in zebrafish models.
- Developing effective treatments for heart failure remains a critical medical need.
Purpose of the Study:
- To investigate the effects of AF-HF001, a novel derivative of AF-001, on cardiomyocytes exposed to oxidative stress.
- To elucidate the molecular mechanisms underlying AF-HF001's protective effects against oxidative damage in heart cells.
- To evaluate the potential of AF-HF001 as a therapeutic agent for heart failure.
Main Methods:
- In vitro assessment of AF-HF001's impact on reactive oxygen species (ROS) production and cardiomyocyte apoptosis.
- DNA microarray analysis to examine gene expression changes induced by hydrogen peroxide (H2O2) with and without AF-HF001 treatment.
- Hierarchical clustering to identify specific genes modulated by AF-HF001 related to cellular processes.
Main Results:
- AF-HF001 significantly attenuated reactive oxygen species (ROS) production and reduced apoptosis in cardiomyocytes subjected to oxidative damage.
- Gene expression analysis revealed that AF-HF001 influences key genes involved in ROS production (e.g., Ndufs2, Ndufs3), cardiac function (e.g., TPM1, MYH14), and extracellular matrix remodeling (e.g., TIMP4).
- The protective effects of AF-HF001 appear to involve the mitogen-activated protein kinase (MAPK) pathway and intrinsic mitochondrial pathways.
Conclusions:
- AF-HF001 demonstrates significant potential in ameliorating oxidative damage in cardiomyocytes, a key factor in heart failure.
- The compound modulates critical gene expression pathways related to cellular stress response, cardiac contractility, and tissue repair.
- AF-HF001 represents a promising drug candidate for future clinical development in the treatment of heart failure.
Abstract:
Heart failure represents a major health problem. The development of new drugs to treat this condition is essential. We previously discovered that AF-001 attenuates the cardiac defects caused by heart failure in zebrafish. In this paper, we report the identification of AF-HF001, an AF-001 derivative, and its effects on live cardiomyocytes subjected to oxidative damage. The in vitro results demonstrated that AF-HF001 attenuates the production of reactive oxygen species (ROS) and the myocardial cell apoptosis. A DNA microarray was performed to broadly analyze gene expression after H2O2 treatment with or without AF-HF001. Hierarchical clustering analysis revealed that AF-HF001 modifies the expression of certain genes (Ndufs2, Ndufb6, Ndufb8, Ndufa13, Ndufs3, Ndufs5, TPM1, MYH14, RyR1, and TIMP4) related to ROS production, cardiac contractility and extracellular matrix remodeling. AF-HF001 ameliorates oxidative damage, which may be related to the mitogen-activated protein kinase (MAPK) family and the intrinsic mitochondrial pathway. Altogether, this study suggests that AF-HF001 exhibits potential as a clinical drug candidate for the treatment of heart failure.
